Admin.
Did you know dumb has a B in it most people don't.
- Reaction score
- 14,412
A new experimental vaccine has shown to reduce the risk of Melanoma recurrence or death by 49% after 5 years.
A new experimental vaccine has shown to reduce the risk of Melanoma recurrence or death by 49% after 5 years. Former Obama White House Health Policy Adviser Dr. Ezekiel Emanuel breaks down what this new therapy could mean for the fight against cancer.
The companies tested the vaccine together with Merck's immunotherapy drug Keytruda, a widely used melanoma treatment. Thousands of patients who have undergone surgery to remove high-risk melanoma tumors could benefit as soon as next year if regulators approve the vaccine, Moderna President Stephen Hoge said in an interview.
A new experimental vaccine has shown to reduce the risk of Melanoma recurrence or death by 49% after 5 years. Former Obama White House Health Policy Adviser Dr. Ezekiel Emanuel breaks down what this new therapy could mean for the fight against cancer.
- Interim analysis shows goals were met for recurrence and preventing cancer spread
- Moderna spikes as much as 160%; Merck jumps 12%
- Barclays estimates therapy could reach about $3 billion in melanoma sales by 2035
The companies tested the vaccine together with Merck's immunotherapy drug Keytruda, a widely used melanoma treatment. Thousands of patients who have undergone surgery to remove high-risk melanoma tumors could benefit as soon as next year if regulators approve the vaccine, Moderna President Stephen Hoge said in an interview.
